Resilience is a technology-driven contract development and manufacturing organization (CDMO) that partners with biopharma innovators to bring biologics, cell-based therapies, and other complex medicines to market more efficiently. The company is actively expanding a North American manufacturing network with end-to-end capabilities in sterile injectable production, device assembly, and packaging. Its Cincinnati site is undergoing a major build-out that is expected to become one of the continent’s largest and most advanced sterile injectable operations, while its Toronto facility anchors additional growth. Resilience positions itself to meet rising demand for on-shoring and reliable supply of advanced therapeutics. The firm has recently strengthened its balance sheet by resolving lease obligations tied to underutilized sites, improving overall operational efficiency. The newly secured long-term capital will fund continued facility expansion and help the company serve customers with greater stability and scale.

Total raised

$1.9B

Funding rounds

5

Latest round

Debt Financing

Latest activity

Oct 2025